Aberrant cytokine signaling in AML is thought to majorly contribute to AML tumorigenesis and progression, with AML-promoting cytokines such as IL1β, IL6, and CXCL12 being investigated for the development of targeted therapies (53). Here, CXCL12 is linked to acute myeloid leukemia.